118th Congress · HOUSE BILLBILL

H.R. 7248FDA Modernization Act 3.0

To amend the Federal Food, Drug, and Cosmetic Act to establish a process for the qualification of nonclinical testing methods to reduce and replace the use of animals in nonclinical research, improve the predictivity of nonclinical testing methods, and reduce development time for a biological product or other drug, and for other purposes.

Health
Introduced Feb 6, 2024
Last action Feb 9, 2024
Pipeline · Bill → Law
Step 1
Introduced
Feb 6, 2024
Step 2
Referred
Feb 9, 2024
E&C
Step 3
Committee
Step 4
House floor
Step 5
Senate
Step 6
Resolve Changes
Step 7
Signed
SummaryCRS Summary

This bill requires the Food and Drug Administration (FDA) to establish a process that supports nonclinical testing methods for drug development that do not involve the use of animals. Specifically, the FDA must establish a pathway by which entities may apply to have nonclinical testing methods approved for use in a particular context. Qualifying methods must be intended to replace or reduce animal testing and to either improve the safety and efficacy of nonclinical testing or reduce the time to develop a drug. The FDA must issue its decision within 180 days of receiving an application. The FDA must also prioritize the review of applications for drugs that are developed using an approved non...

Provisions · 3 sectionsIntroduced in House
Timeline · 3 actions
Feb 9, 2024
Referred to the Subcommittee on Health.
Feb 6, 2024
Introduced in House
Feb 6, 2024
Referred to the House Committee on Energy and Commerce.